Cancer-directed treatments separated into first-line treatments and R/R treatments by the number of studies in each group
| First-line treatment–focused studies (N = 83) . | n (%) . |
|---|---|
| Chemotherapy | |
| ABVD | 59 (71) |
| MOPP, COPP, or BEACOPP | 15 (18) |
| CVPP or AOPE | 1 (1) |
| EVAP | 1 (1) |
| Other | 2 (2) |
| Unspecified | 5 (6) |
| Radiotherapy | |
| Widely used | 58 (70) |
| Rarely used | 10 (12) |
| Not used or not reported | 15 (18) |
| R/R HL studies (N = 29) | |
| Primary advanced treatments used | |
| High-dose chemotherapy and ASCT | 18 (62) |
| Nivolumab | 3 (10) |
| Brentuximab vedotin | 3 (10) |
| Sintilimab | 1 (3) |
| Zimberelimab (GSL-010) | 1 (3) |
| Everolimus | 1 (3) |
| Allogeneic SCT | 1 (3) |
| ABVD | 1 (3) |
| Other | 1 (3) |
| Radiotherapy | |
| Widely used | 17 (59) |
| Rarely used or not used | 12 (41) |
| First-line treatment–focused studies (N = 83) . | n (%) . |
|---|---|
| Chemotherapy | |
| ABVD | 59 (71) |
| MOPP, COPP, or BEACOPP | 15 (18) |
| CVPP or AOPE | 1 (1) |
| EVAP | 1 (1) |
| Other | 2 (2) |
| Unspecified | 5 (6) |
| Radiotherapy | |
| Widely used | 58 (70) |
| Rarely used | 10 (12) |
| Not used or not reported | 15 (18) |
| R/R HL studies (N = 29) | |
| Primary advanced treatments used | |
| High-dose chemotherapy and ASCT | 18 (62) |
| Nivolumab | 3 (10) |
| Brentuximab vedotin | 3 (10) |
| Sintilimab | 1 (3) |
| Zimberelimab (GSL-010) | 1 (3) |
| Everolimus | 1 (3) |
| Allogeneic SCT | 1 (3) |
| ABVD | 1 (3) |
| Other | 1 (3) |
| Radiotherapy | |
| Widely used | 17 (59) |
| Rarely used or not used | 12 (41) |
AOPE, cytarabine, vincristine, cisplatin, and etoposide; EVAP, etoposide, vinbastine, doxorubucin, and prednisone; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; COPP, cyclophosphamide, vincristine, procarbazine, and prednisone; CVPP, cyclophosphamide, vinblastine, procarbazine, and prednisone; MOPP, mechlorethamin, vincristine, procarbazine, and prednisone.